New Strong Buy Stocks for September 18th

Zacks added Pagaya Technologies, OptimumBank Holdings, Pro-Dex, Travelers and Horace Mann Educators to its Rank #1 (Strong Buy) list after current-year consensus EPS estimates rose 6.2%-16.5% over the past 60 days. The largest revisions were for OptimumBank (+16.5%), Pagaya (+15.2%) and Travelers (+13.7%). The upgrades are favorable analyst signals but are unlikely to have broad market impact.

Analysis

This is a low-information factor signal, not a fundamental catalyst: estimate revisions can attract short-horizon quant and retail flows, but the listed names have materially different liquidity and earnings-quality profiles. PGY and OPHC are most vulnerable to a transient momentum bid because their smaller-cap investor bases can amplify flows, while PDEX carries execution and customer-concentration risk that a consensus EPS change does not resolve. Treat any initial move as a liquidity event unless subsequent filings validate revenue, credit, or order-book improvement.

Within insurance, TRV and HMN should not be grouped. TRV's scale and diversified commercial exposure make a modest revision less likely to alter valuation, whereas HMN's educator-focused book has greater sensitivity to retention, wage inflation, catastrophe/reinsurance costs, and investment income. The more useful read-through is whether improving insurer estimates reflect durable pricing and favorable loss trends; if so, regional carriers could see delayed revisions, but a renewed reserve-strengthening cycle would reverse the group signal quickly.

For PGY, the key falsification is not another EPS revision but credit performance: delinquency/vintage trends, partner-bank funding capacity, take-rate durability, and the residual economics of its asset-backed structures. A risk-off move or wider consumer ABS spreads can impair funding economics before reported earnings deteriorate, making a simple long based on revisions asymmetrically exposed over the next 1-3 months. No standalone trade is warranted in OPHC or PDEX without average daily dollar-volume, revised estimates, valuation, and next-quarter guidance data.

Key Decisions for Investors

• Do not chase the publication-day signal; place PGY on a 1-3 month watchlist and consider a tactical long only after its next results confirm stable credit vintages and funding spreads. Exit on evidence of worsening delinquencies, ABS-spread widening, or a reduction in transaction-volume guidance.
• Use TRV as the higher-liquidity insurance expression only if upcoming earnings show favorable prior-year development and management sustains pricing above loss-cost inflation; target a 3-6 month holding period. Falsify on reserve strengthening or a material catastrophe-loss revision, and avoid paying up for a revision-driven multiple expansion alone.
• Monitor a potential long TRV / short HMN pair after both companies report: it isolates scale and commercial-pricing resilience from HMN's more concentrated specialty exposure. Initiate only if relative valuation is not already extended and if HMN's retention or combined-ratio outlook weakens; reassess within one earnings cycle.
• Avoid OPHC and PDEX absent confirmation of sufficient trading liquidity and fundamental disclosures. For PDEX, require order backlog, OEM customer concentration, and gross-margin trajectory; for OPHC, require deposit-cost, uninsured-deposit, CRE exposure, and loan-loss-reserve data before sizing any position.